tiprankstipranks
ConvaTec (CH:2CV)
:2CV

ConvaTec (2CV) Price & Analysis

0 Followers

2CV Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.

Bulls Say, Bears Say

Bulls Say
Consistent Organic GrowthA multi-year record of >5% organic growth (6.4% in 2025 ex‑InnovaMatrix) indicates resilient demand in chronic-care consumables and recurring revenue. This durability underpins predictable cashflows, supports capacity investment and makes multi-year growth targets (6–8%) credible.
Margin ExpansionSustained operating margin improvement reflects effective pricing, productivity and simplification programs that generated structural cost advantages. Management targets mid‑20s margins, implying ongoing operating leverage that can support long-term profit quality despite inflationary headwinds.
Strong Free Cash Flow & Capital ReturnsConsistently high FCF conversion (101% in 2025) funds growth CapEx, buybacks and dividends without defaulting to equity raises. Reliable cash generation improves financial flexibility for reinvestment, debt paydown or shareholder returns over the medium term.
Bears Say
Rising LeverageA marked step-up in leverage reduces balance‑sheet flexibility and raises sensitivity to earnings and interest-rate shocks. At higher net debt/EBITDA targets (~2x), the company has less room for cyclical setbacks, M&A or sustained buybacks without constraining liquidity or credit capacity.
Regulatory Quality Risk (FDA)An FDA warning on complaints and CAPA processes forces remediation, possible inspections and closer regulator scrutiny. Fixing quality systems can be time-consuming and costly, potentially delaying product launches, limiting sales in regulated markets and creating longer-term reputational risk.
Reimbursement/Acquisition Shock (InnovaMatrix)A severe CMS reimbursement cut leading to a sizable impairment highlights material exposure to policy changes and post‑acquisition execution risk. Recovery is uncertain given channel disruption, legal challenges and competitor inventory, creating a sustained revenue and profitability overhang in the medium term.

ConvaTec News

2CV FAQ

What was ConvaTec’s price range in the past 12 months?
Currently, no data Available
What is ConvaTec’s market cap?
ConvaTec’s market cap is CHF4.22B.
    When is ConvaTec’s upcoming earnings report date?
    ConvaTec’s upcoming earnings report date is Aug 04, 2026 which is in 50 days.
      How were ConvaTec’s earnings last quarter?
      ConvaTec released its earnings results on Feb 24, 2026. The company reported CHF0.076 earnings per share for the quarter, missing the consensus estimate of CHF0.079 by -CHF0.002.
        Is ConvaTec overvalued?
        According to Wall Street analysts ConvaTec’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does ConvaTec pay dividends?
          ConvaTec does not currently pay dividends.
          What is ConvaTec’s EPS estimate?
          ConvaTec’s EPS estimate is 0.07.
            How many shares outstanding does ConvaTec have?
            ConvaTec has 1,954,852,000 shares outstanding.
              What happened to ConvaTec’s price movement after its last earnings report?
              ConvaTec reported an EPS of CHF0.076 in its last earnings report, missing expectations of CHF0.079. Following the earnings report the stock price went same N/A.
                Which hedge fund is a major shareholder of ConvaTec?
                Currently, no hedge funds are holding shares in CH:2CV
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  ConvaTec

                  ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.

                  ConvaTec (2CV) Earnings & Revenues

                  2CV Stock 12 Month Forecast

                  Average Price Target

                  CHF3.22
                  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
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Advanced Medical Solutions
                  CVS Group plc
                  Tristel
                  Smith & Nephew

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks